Prosecution Insights
Last updated: November 20, 2026
Application No. 16/985,891

LONG-TERM RE-ABSORBABLE SUBCUTANEOUS IMPLANT WITH CONTROLED PRE-CONCENTRATED PHARMACOLOGICALLY ACTIVE POLYMER SUBSTANCE RELEASE FOR TREATING ENDOMETRIOSIS

Final Rejection §103
Filed
Aug 05, 2020
Priority
Apr 17, 2020 — BR BR 1020200077490
Examiner
ALAM, AYAAN A
Art Unit
1611
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
None recorded (individual inventor: Edson Luiz Peracchi)
OA Round
7 (Final)
39%
Grant Probability
At Risk
8-9
OA Rounds
0m
Est. Remaining
75%
With Interview

Examiner Intelligence

Grants only 39% of cases
39%
Career Allowance Rate
59 granted / 153 resolved
-21.4% vs TC avg
Strong +37% interview lift
Without
With
+36.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
53 currently pending
Career history
222
Total Applications
across all art units

Statute-Specific Performance

§101
2.9%
-37.1% vs TC avg
§103
54.1%
+14.1% vs TC avg
§102
11.1%
-28.9% vs TC avg
§112
22.1%
-17.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 153 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In view of the Appeal Brief filed on 02/19/2026, PROSECUTION IS HEREBY REOPENED. New grounds of rejections are set forth below. To avoid abandonment of the application, appellant must exercise one of the following two options: (1) file a reply under 37 CFR 1.111 (if this Office action is non-final) or a reply under 37 CFR 1.113 (if this Office action is final); or, (2) initiate a new appeal by filing a notice of appeal under 37 CFR 41.31 followed by an appeal brief under 37 CFR 41.37. The previously paid notice of appeal fee and appeal brief fee can be applied to the new appeal. If, however, the appeal fees set forth in 37 CFR 41.20 have been increased since they were previously paid, then appellant must pay the difference between the increased fees and the amount previously paid. A Supervisory Patent Examiner (SPE) has approved of reopening prosecution by signing below: /BETHANY P BARHAM/ Supervisory Patent Examiner, Art Unit 1611 Status of Claims The arguments filed on 02/19/2026 are acknowledged and have been fully considered. Claims 15-21 are now pending. Claims 1-14 are canceled. Claims 15-21 will be examined on the merits herein. Modified Rejections Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 15-21 are rejected under 35 U.S.C. 103 as being unpatentable over US PGPUB 20190298646 A1 (Allred, 2019) in view of US PGPUB 20070031472 A1 (Huang et al., 2007; referred to as Huang herein). In regards to claims 15 and 17, Allred teaches a biodegradable sustained release implant (see e.g., ¶[0048]) comprising a steroid, such as gestrinone (see e.g., ¶[0019]) in a polymeric matrix comprised of polylactide, polyglycolide, polyvinyl pyrrolidone, polyvinyl alcohol, cross-linked poly (ethylene oxide), among others (see e.g., ¶[0025]). Further, Allred teaches that the composition may contain a polymer matrix and about 2% to about 85% of one or more anti-inflammatory agents (i.e., a steroid, such as gestrinone) by weight of the total composition (see e.g., ¶[0026]). Assuming the amount of the anti-inflammatory agent is 85% by weight, the 15% leftover comprises the polymeric matrix materials. MPEP §2144.05(I) states that "[i]n the case where the claimed ranges 'overlap or lie inside ranges disclosed by the prior art' a prima facie case of obviousness exists" quoting In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976). It is also taught that the sustained release composition releases the anti-inflammatory agent from about 1 week to about 6 months (see e.g., ¶[0029], ¶[0032]) (i.e., the effective implant duration time). Further in regard to claims 15 and 18, Allred teaches that the release period of the anti-inflammatory agent is from about 2 days to about 4 days (see e.g., ¶[0040]). Allred also teaches that the composition releases from 10 to 20 mg/day. A composition that releases 10 to 20 mg/day for 2 days comprises at least 40 mg of the anti-inflammatory agent. MPEP §2144.05(I) states that "[i]n the case where the claimed ranges 'overlap or lie inside ranges disclosed by the prior art' a prima facie case of obviousness exists" quoting In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976). In regards to claim 19, Allred teaches that the implant has a cylindrical or rod-shaped structure (see e.g., ¶[0034]). Allred is silent on the gestrinone homogeneously dispersed in the polymeric matrix, the size of the cylindrical or rod-shaped implant, and a coating on the implant. In regards to claim 15 and 21, Huang teaches an implant comprising a steroid and a biodegradable polymer matrix (see e.g., Abstract). The steroid is taught to be in particle form (see e.g., ¶[0074]) and homogeneously dispersed throughout the implant (see e.g., ¶[0059]). Huang teaches that the implant comprises one or more coating (see e.g., ¶[0099]) comprising poly(dimethylsiloxane) (see e.g., ¶[0105]-[0106]) or polyglycolic acid copolymer (see e.g., ¶[0084]). In regards to claim 19, Huang teaches that the implant is in the shape of a cylindrical pellet (e.g., a rod) with the length of about 7 mm to about 10 mm and a diameter of about 0.75 mm to about 1.5 mm. MPEP §2144.05(I) states that "[i]n the case where the claimed ranges 'overlap or lie inside ranges disclosed by the prior art' a prima facie case of obviousness exists" quoting In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976). In regards to claims 15-21, it would have been prima facie obvious to a person of ordinary skill in the art, before the effective filing date of the claimed invention, to formulate an implant comprising gestrinone in particles dispersed homogeneously in a polymeric matrix using the teachings of Allred and Huang as both references teach implants that release steroids over time. Further, Allred and Huang teach the same steroids in the composition (fluocinolone, triamcinolone, beclomethasone (see e.g., Huang, ¶[0074]; Allred, ¶[0020]). As both references have overlap in the active agent, it would be obvious to one with ordinary skill in the art to use another steroid, such as gestrinone (as taught in Allred), which has a similar structure as the steroids mentioned above, in particle form and homogeneously dispersed in polymeric matrix (as taught by Huang). It would be obvious to one with ordinary skill in the art to combine the gestrinone of Allred with the implant of Huang according to the known method of making an implant (see e.g., Allred, ¶[0034]) to yield the predictable results of reducing inflammation with a reasonable expectation of success. It would be obvious to one with ordinary skill in the art to combine prior art elements according to known method to yield predictable results. In regards to claim 16, where the claimed and prior art products are identical or substantially identical in structure or composition, or are produced by identical or substantially identical processes, a prima facie case of either anticipation or obviousness has been established. In re Best, 562 F.2d 1252, 1255, 195 USPQ 430, 433 (CCPA 1977). In the instant case, the prior art renders obvious the instant composition a person of ordinary skill in the art would reasonably expect the same composition to have the same properties (i.e., release being proportional to the square root of the implant duration time in vivo) as instantly claimed. Further, Allred teaches that the composition releases the anti-inflammatory agent at a rate of about 0.01 to about 10 mg/day (see Allred, paragraph 0060). MPEP §2144.05(I) states that "[i]n the case where the claimed ranges 'overlap or lie inside ranges disclosed by the prior art' a prima facie case of obviousness exists" quoting In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976). Further in regards to claim 20, specifically to the limitation of the “thickness between 0.1 to 0.7mm,” that the properties of the coating, such as thickness, are able to be adjusted for optimal delivery of the steroid in the implant (see e.g., Huang, ¶[0114] and ¶[0228]). As such, the thickness of the coating would have been considered a result effective variable by one having ordinary skill in the art before the effective filing date of the invention. As such, without showing unexpected results, the claimed thickness cannot be considered critical. Accordingly, one of ordinary skill in the art before the effective filing date of the invention would have optimized, by routine experimentation, thickness of the coating in Huang to obtain the desired balance between the optimal delivery of the steroid as taught by Huang (In re Boesch, 617 F.2d. 272, 205 USPQ 215 (CCPA 1980)), since it has been held that where the general conditions of the claim are disclosed in the prior art, discovering the optimum or workable ranges involves only routine skill in the art. (In re Aller, 105 USPQ 223). “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” See In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). The discovery of an optimum value of a known result effective variable, without producing any new or unexpected results, is within the ambit of a person of ordinary skill in the art. See In re Boesch, 205 USPQ 215 (CCPA 1980). See MPEP §2144.05(II). Response to Arguments Appellant's arguments filed 02/19/2026 have been fully considered but they are not persuasive in view of the modified grounds of rejection. In regards to appellant’s argument the use of gestrinone is mentioned in a laundry list of hormones in the Allred publication (referred to as Allred hereinafter), it is pointed out that it is part of the literature. "The use of patents as references is not limited to what the patentees describe as their own inventions or to the problems with which they are concerned. They are part of the literature of the art, relevant for all they contain." In re Heck, 699 F.2d 1331, 1332-33, 216 USPQ 1038, 1039 (Fed. Cir. 1983). Further, Allred and Huang teach the same steroids in the composition (fluocinolone, triamcinolone, beclomethasone (see e.g., Huang, ¶[0074]; Allred, ¶[0020]). As both references have overlap in the active agent, it would be obvious to one with ordinary skill in the art to use another steroid, such as gestrinone (as taught in Allred), which has a similar structure as the steroids mentioned above, in particle form and homogeneously dispersed in polymeric matrix (as taught by Huang). One cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See In re Keller, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); In re Merck & Co., 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). In regards to appellant’s argument that Allred does not mention the treatment of endometriosis, it is pointed out that neither do the claims. There is no mention of endometriosis in the claims and as such, there is no bearing of it on the patentability of the claims. It is also noted that the treatment of endometriosis is a future intended use, however the future intended use of a product is not considered to contribute to the overall patentability of the instant invention, particularly when the product itself is claimed and that same product is taught in the prior art. Further appellant argues that Allred does not teach a bio-absorbable polymeric matrix with a polymeric coating membrane to provide a calculated implant with a duration time and a calculated gestrinone release rate, an implant with a duration time in vivo between 4.5 months to 6 months for the effective treatment for the symptoms of endometriosis, or a gestrinone release in vivo that is proportional to the square root of time in vivo. It is pointed out that the rejection is made in view of Allred and Huang, not just Huang. It is pointed out that Allred teaches that the sustained release composition releases the anti-inflammatory agent from about 1 week to about 6 months (see e.g., ¶[0029], ¶[0032]) (i.e., the effective implant duration time). The teachings of both references have been described in detail above. The combination of both references would motivate one with ordinary skill in the art to combine the gestrinone of Allred with the implant of Huang according to the known method of making an implant (see e.g., Allred, ¶[0034]) to yield the predictable results of reducing inflammation with a reasonable expectation of success. It would be obvious to one with ordinary skill in the art to combine prior art elements according to known method to yield predictable results. Further, appellant argues that the preferred embodiment of Allred releases 50% of the active ingredient in weeks 1-3, however it is pointed out that "The use of patents as references is not limited to what the patentees describe as their own inventions or to the problems with which they are concerned. They are part of the literature of the art, relevant for all they contain." In re Heck, 699 F.2d 1331, 1332-33, 216 USPQ 1038, 1039 (Fed. Cir. 1983). Allred also teaches that the active ingredient is released in varying rates for varying durations (see e.g., Allred ¶[0031-0033]). Appellant’s arguments with respect to reference Xue have been considered but are moot because the new ground of rejection does not rely on the Xue reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. In regards to appellant’s argument that the claimed invention is substantially different than the teachings of Allred in terms of critical functional proportion since a formulation with 1 to 20% polymer is claimed, it is pointed out that Allred teaches that the composition may contain a polymer matrix and about 2% to about 85% of one or more anti-inflammatory agents (i.e., a steroid, such as gestrinone) by weight of the total composition (see e.g., ¶[0026]). Assuming the amount of the anti-inflammatory agent is 85% by weight, the 15% leftover comprises the polymeric matrix materials. MPEP §2144.05(I) states that "[i]n the case where the claimed ranges 'overlap or lie inside ranges disclosed by the prior art' a prima facie case of obviousness exists" quoting In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976). These amounts of polymer and steroid are within the claimed amounts. Appellant further argues that Allred does not teach a specific dose for gestrinone, however Allred teaches that the release period of the anti-inflammatory agent is from about 2 days to about 4 days (see e.g., ¶[0040]). Allred also teaches that the composition releases from 10 to 20 mg/day. A composition that releases 10 to 20 mg/day for 2 days comprises at least 40 mg of the anti-inflammatory agent. MPEP §2144.05(I) states that "[i]n the case where the claimed ranges 'overlap or lie inside ranges disclosed by the prior art' a prima facie case of obviousness exists" quoting In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976). Allred does teach that the anti-inflammatory agent is gestrinone (see e.g., ¶[0019]). Further appellant argues that the release of the gestrinone is due to the subcutaneous implants being composed of bioabsorbable polymeric matrices that homogeneously contain gestrinone, however Huang teaches an implant comprising a steroid and a biodegradable polymer matrix (see e.g., Abstract). The steroid is taught to be in particle form (see e.g., ¶[0074]) and homogeneously dispersed throughout the implant (see e.g., ¶[0059]). Appellant then mentions that the coating is a notable aspect to regulate the release, however Huang teaches that the implant comprises one or more coating (see e.g., ¶[0099]) comprising poly(dimethylsiloxane) (see e.g., ¶[0105]-[0106]) or polyglycolic acid copolymer (see e.g., ¶[0084]). Again, the structural components of the instant claims are being met, and as such, one with ordinary skill in the art would understand that the release rate would be identical as claimed and without data or evidence to show otherwise, the instant claims are rendered obvious. To say another way, the art renders the structure and components of the claimed invention, and as such it would be understood that the property of how much of the gestrinone is released would be the same as instantly claimed as well. In order to overcome this, appellant is suggested to show data that indicate this is not the case (e.g., through unexpected results). For the foregoing reasons, Appellant’s remarks are not persuasive. Therefore, the references of record continue to teach the instantly claimed composition. It is recommended that appellant submit additional data or evidence to support the claims of unexpected results in order to overcome the rejection of record. Conclusion No claims allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to AYAAN A ALAM whose telephone number is (571)270-1213. The examiner can normally be reached M-F 8-5 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bethany Barham can be reached at 571-272-6175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BETHANY P BARHAM/Supervisory Patent Examiner, Art Unit 1611 /A.A.A./ Examiner, Art Unit 1611
Read full office action

Prosecution Timeline

Show 17 earlier events
Dec 16, 2025
Notice of Allowance
Feb 19, 2026
Response after Non-Final Action
Mar 10, 2026
Response after Non-Final Action
May 13, 2026
Non-Final Rejection mailed — §103
Aug 12, 2026
Response Filed
Aug 12, 2026
Response after Non-Final Action
Sep 01, 2026
Response Filed
Nov 18, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799336
SURFACE-TREATED METAL OXIDE PARTICLES, DISPERSION LIQUID, COSMETIC AND METHOD FOR PRODUCING SURFACE-TREATED METAL OXIDE PARTICLES
4y 1m to grant Granted Nov 17, 2026
Patent 12746256
TOPICAL COMPOSITION FOR TREATMENT OF PAIN AND SYMPTOMS ASSOCIATED WITH RHINOSINUSITIS, METHOD OF MAKING, AND METHOD OF USE
5y 3m to grant Granted Sep 29, 2026
Patent 12745777
FERRATE COMPOSITIONS FOR SURFACE DISINFECTION
3y 9m to grant Granted Sep 29, 2026
Patent 12714098
AGROCHEMICAL ELECTROLYTE COMPOSITIONS
6y 8m to grant Granted Aug 25, 2026
Patent 12702643
Ion-Exchange Composition With Water-Soluble Mucoadhesive Polymers
6y 10m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

8-9
Expected OA Rounds
39%
Grant Probability
75%
With Interview (+36.7%)
3y 3m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 153 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month